Human Relaxin-2 ELISA Kit - Quantikine

Catalog # Availability Size / Price Qty
DRL200
Control Products Available
Human Relaxin-2 ELISA Cell Culture Supernate Standard Curve
3 Images
Product Details
Procedure
Citations (13)
FAQs
Supplemental Products
Reviews

Human Relaxin-2 Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL)
Sensitivity
4.57 pg/mL
Assay Range
7.8 - 500 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma)
Specificity
Natural and recombinant human Relaxin-2
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference
No significant interference observed with available related molecules.

Product Summary

The Quantikine Human Relaxin-2 Immunoassay is a 4.5 hour solid phase ELISA designed to measure human Relaxin-2 in cell culture supernates, serum, and plasma. It contains E. coli-expressed recombinant human Relaxin-2 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human Relaxin-2 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human Relaxin-2.

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision

Cell Culture Supernates

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 41 41 41
Mean (pg/mL) 35.1 96 194 34.9 98.9 197
Standard Deviation 1.27 2.44 4.01 3.41 5.9 11.7
CV% 3.6 2.5 2.1 9.8 6 5.9

Serum, EDTA Plasma, Heparin Plasma

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 42 42 42
Mean (pg/mL) 34.4 99.6 206 40.8 112 220
Standard Deviation 1.6 2.47 4.75 4.16 7.02 12.1
CV% 4.7 2.5 2.3 10.2 6.3 5.5

Recovery

The recovery of Relaxin-2 spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 95 89-102
EDTA Plasma (n=4) 98 93-106
Heparin Plasma (n=4) 97 91-104
Serum (n=4) 101 92-107

Linearity

To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Relaxin-2 were serially diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human Relaxin-2 ELISA Linearity

Scientific Data

Human Relaxin-2 ELISA Cell Culture Supernate Standard Curve

Human Relaxin-2 ELISA Serum/Plasma Standard Curve

Product Datasheets

You must select a language.

x

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Relaxin-2

The Insulin/Relaxin superfamily includes Insulin, IGF-I, IGF-II, Relaxins, Relaxin-like Factor (RLF), Early Placenta Insulin-like Peptide 4 (INSL4), INSL5, and INSL6. Three human Relaxin genes (Relaxins-1 to -3) have been identified. Relaxin-2 is secreted and circulates in the blood, whereas Relaxin-1 is expressed in decidua, placenta, and prostate, and Relaxin-3 is expressed in the brain. Human Relaxin-2 is a peptide hormone that plays an important role in female reproduction.

Entrez Gene IDs:
6019 (Human)
Alternate Names:
bA12D24.1.1; bA12D24.1.2; H2; relaxin 2; Relaxin2; Relaxin-2; RLN2; RLXH2
&#9888; WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

  3. 100 µL Assay Diluent
  4.   Add 100 µL of Assay Diluent to each well.

  5. 50 µL Standard, Control, or Sample
  6.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours.
  7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

  8. 200 µL Conjugate
  9.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours.
  10.   Aspirate and wash 4 times.

  11. 200 µL Substrate Solution
  12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.

  13. 50 µL Stop Solution
  14.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human Relaxin-2 Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

13 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Study protocol to investigate biomolecular muscle profile as predictors of long-term urinary incontinence in women with gestational diabetes mellitus
    Authors: MVC Rudge, FP Souza, JF Abbade, RLS Hallur, JPC Marcondes, F Piculo, G Marini, G Vesentini, L Thabane, SS Witkin, IMP Calderon, AMP Barbosa, MV Rudge, AMP Barbosa, IMP Calderon, FP Souza, JF Abbade, LSR Hallur, F Piculo, G Marini, G Vesentini, L Thabane, MS Palma, CFO Graeff, RK Arni, RD Herculano, DF Salvadori, S Mateus, M Dal Pai Si, CG Magalhães, RA Costa, SAM Lima, SL Felisbino, W Barbosa, A Atallah, MJB Girão, Z Di Bella, SM Uchoa, S Payão, A Hijas, B Berghman, R De Bie, L Sobrevia, B Junginger, FCB Alves, PS Rossignoli, CB Prudencio, MIG Orlandi, MI Gonçalves, SK Nunes, BB Catinelli, S Quiroz, BV Sarmento, FA Pinheiro, CI Sartorão, RR Lucas, DRA Reyes, SBCV Quiroz, EMA Enriquez, RG Oliveira, JF Floriano, JPC Marcondes, S Barneze, TD Dangió, T Pascon, P Rossignoli, JV Freitas, L Takano, F Reis, TD Caldeirão, JN Fernandes, AM Carr, MVC Gaitero, JE Corrente, HRC Nunes, AF Candido, SMB Costa, TD Dangió, T Pascon, JVF Melo, L Takano, FVDS Reis, TD Caldeirão, AM Carr, GA Garcia, GB Rabadan, HCM Bassin, KS Suyama, LN Damasceno, MLS Takemoto, MD Menezes, DG Bussaneli, VKC Nogueira, PR Lima, IO Lourenço, J Marostica, RA Megid, IP Caruso, LT Rasmussen, GM Prata, F Piculo, G Vesentini, MA Arantes, GAR Ferraz, LP Camargo, MR Kron, JE Corrente, HRC Nunes
    BMC Pregnancy Childbirth, 2020-02-19;20(1):117.
    Species: Human
    Sample Types: Serum
  2. Serelaxin Improves Regional Myocardial Function in Experimental Heart Failure: An In Vivo Cardiac Magnetic Resonance Study
    Authors: T Lapinskas, S Kelle, J Grune, A Foryst-Lud, H Meyborg, S Jeuthe, E Wellnhofer, A Elsanhoury, B Pieske, R Gebker, U Kintscher, P Stawowy
    J Am Heart Assoc, 2020-01-31;9(3):e013702.
    Species: Mouse
    Sample Types: Plasma
  3. Relaxin reverses maladaptive remodeling of the aged heart through Wnt-signaling
    Authors: B Martin, B Gabris, AF Barakat, BL Henry, M Giannini, RP Reddy, X Wang, G Romero, G Salama
    Sci Rep, 2019-12-06;9(1):18545.
    Species: Rat
    Sample Types: Plasma
  4. Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
    Authors: J Simon, E Nemeth, A Nemes, M Husveth-To, T Radovits, G Foldes, L Kiss, Z Bagyura, J Skopal, B Merkely, E Gara
    Front Physiol, 2019-06-04;10(0):690.
    Species: Human
    Sample Types: Serum
  5. Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
    Authors: JA Luetkens, AC Wolpers, T Beiert, D Kuetting, D Dabir, R Homsi, H Meenderman, NA Dayé, V Knappe, M Karsdal, SH Nielsen, F Genovese, F Stöckigt, M Linhart, D Thomas, G Nickenig, HH Schild, JW Schrickel, RP Andrié
    Sci Rep, 2018-09-11;8(1):13618.
    Species: Human
    Sample Types: Plasma
  6. Associations between serum relaxin 2, aneurysm formation/size and severity of atherosclerosis: a preliminary prospective analysis
    Authors: K Papoutsis, A Kapelouzou, DI Tsilimigra, N Patelis, G Kouvelos, D Schizas, I Karavokyro, S Georgopoul
    Acta Pharmacol. Sin., 2018-03-22;0(0):.
    Species: Human
    Sample Types: Serum
  7. Short-term (48 hours) intravenous serelaxin infusion has no effect on myogenic tone or vascular remodeling in rat mesenteric arteries
    Authors: M Jelinic, CH Leo, SA Marshall, SN Senadheera, LJ Parry, M Tare
    Microcirculation, 2017-08-01;0(0):.
    Species: Rat
    Sample Types: Plasma
  8. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism
    Authors: J Valle Rale, AG Mauro, T Devarakond, C Marchetti, J He, E Kim, S Filippone, A Das, S Toldo, A Abbate, FN Salloum
    Cardiovasc. Res, 2017-05-01;0(0):.
    Species: Human
    Sample Types: Plasma
  9. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial
    Authors: VK Snowdon, NJ Lachlan, AM Hoy, PW Hadoke, SI Semple, D Patel, W Mungall, TJ Kendall, A Thomson, RJ Lennen, MA Jansen, CM Moran, A Pellicoro, P Ramachandr, I Shaw, RL Aucott, T Severin, R Saini, J Pak, D Yates, N Dongre, JS Duffield, DJ Webb, JP Iredale, PC Hayes, JA Fallowfiel
    PLoS Med, 2017-02-28;14(2):e1002248.
    Species: Human, Rat
    Sample Types: Serum
  10. Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes
    Authors: HH Ng, CH Leo, D Prakoso, C Qin, RH Ritchie, LJ Parry
    Sci Rep, 2017-01-09;7(0):39604.
    Species: Mouse
    Sample Types: Plasma
  11. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.
    Authors: Jelinic M, Leo C, Post Uiterweer E, Sandow S, Gooi J, Wlodek M, Conrad K, Parkington H, Tare M, Parry L
    FASEB J, 2013-09-13;28(1):275-87.
    Species: Rat
    Sample Types: Plasma
  12. Relaxin regulates hyaluronan synthesis and aquaporins in the cervix of late pregnant mice.
    Authors: Soh, Yu May, Tiwari, Anjana, Mahendroo, Mala, Conrad, Kirk P, Parry, Laura J
    Endocrinology, 2012-10-19;153(12):6054-64.
    Species: Human
    Sample Types: Complex Sample Type
  13. Serum relaxin levels are reduced in pregnant women with a history of recurrent miscarriage, and correlate with maternal uterine artery Doppler indices in first trimester.
    Authors: Anumba DO, El Gelany S, Elliott SL
    Eur. J. Obstet. Gynecol. Reprod. Biol., 2009-08-19;147(1):41-5.
    Species: Human
    Sample Types: Serum

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs
Loading...

Reviews for Human Relaxin-2 Quantikine ELISA Kit

There are currently no reviews for this product. Be the first to review Human Relaxin-2 Quantikine ELISA Kit and earn rewards!

Have you used Human Relaxin-2 Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review